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Shared Epitope–Antagonistic Ligands
A New Therapeutic Strategy in Mice With Erosive Arthritis
Song Ling,1 Ying Liu,1 Jiaqi Fu,1 Alessandro Colletta,1 Chaim Gilon,2 and Joseph Holoshitz1
Objective. The mechanisms underlying bone
damage in rheumatoid arthritis (RA) are incompletely
understood. We recently identified the shared epitope
(SE), an HLA–DRB1–coded 5–amino acid sequence
motif carried by the majority of RA patients as a signal
transduction ligand that interacts with cell surface cal-
reticulin and accelerates osteoclast (OC)–mediated
bone damage in collagen-induced arthritis (CIA). Given
the role of the SE/calreticulin pathway in arthritis-
associated bone damage, we sought to determine the
therapeutic targetability of calreticulin.
Methods. A library of backbone-cyclized peptido-
mimetic compounds, all carrying an identical core
DKCLA sequence, was synthesized. The ability of these
compounds to inhibit SE-activated signaling and OC
differentiation was tested in vitro. The effect on disease
severity and OC-mediated bone damage was studied by
weekly intraperitoneal administration of the com-
pounds to DBA/1 mice with CIA.
Results. Two members of the peptidomimetics
library were found to have SE-antagonistic effects and
antiosteoclast differentiation effects at picomolar concen-
trations in vitro. The lead mimetic compound, designated
HS(4-4)c Trp, potently ameliorated arthritis and bone
damage in vivo when administered in picogram doses to
mice with CIA. Another mimetic analog, designated
HS(3-4)c Trp, was found to lack activity, both in vitro
and in vivo. The differential activity of the 2 analogs
depended on minor differences in their respective ring
sizes and correlated with distinctive geometry when com-
putationally docked to the SE binding site on calreticulin.
Conclusion. These findings identify calreticulin
as a novel therapeutic target in erosive arthritis and
provide sound rationale and early structure/activity
relationships for future drug design.
Despite the advent of biologic agents, preventing
bone damage in rheumatoid arthritis (RA) remains a
challenging endeavor. Due to insufficient understanding
of the mechanisms that trigger RA onset and determine
disease severity, most current and emerging drugs are
targeted at generic “downstream” immune pathways or
inflammatory cytokines. As a result, drug failure and/or
side effects are all too common.
The etiology and pathogenesis of RA are incom-
pletely understood. However, it has long been observed
that the majority of RA patients carry HLA–DRB1
alleles that code a 5–amino acid sequence motif called
the “shared epitope” (SE) in region 70–74 of the DRb
chain (1). The SE not only confers a higher risk of RA,
but it also increases the likelihood of developing more
severe disease. SE-coding HLA–DRB1 alleles are asso-
ciated with earlier disease onset and accelerated bone
damage (2–5). Furthermore, there is evidence of a
gene-dose effect, where the extent of bone destruction
in RA correlates positively with the number of SE-
coding HLA–DRB1 alleles (3–5).
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The underlying mechanisms by which the SE
affects susceptibility to, or the severity of, RA are
unknown. We have recently identified the SE as a signal
transduction ligand that binds to a well-defined site on
cell surface calreticulin (6) in a strictly allele-specific
manner and activates nitric oxide–mediated signaling
(7–11), with resultant enhanced osteoclast (OC) differ-
entiation and activation both in vitro and in vivo (12,13).
OC-mediated bone damage is a common and
unfortunate outcome in RA (14,15). In addition to
juxtaarticular bone erosion, RA patients also experience
periarticular and systemic osteoporosis (16). The com-
mon mechanism underlying these pathologic changes of
bone is believed to involve dysregulation of the balance
between bone formation and resorption due to excessive
cellular activity of OCs (17) as a result of intricate cross-
talk with other cells in the synovium that produce
RANKL (18–20).
In previous studies, we demonstrated that the SE
ligand has a dual enhancing effect on OC differentiation
and activation in vitro: an indirect effect through polar-
ization toward RANKL-expressing Th17 cells and a
direct differentiation effect on OC precursors. When
administered in vivo to mice with collagen-induced
arthritis (CIA), the SE ligand was shown to increase
joint swelling, abundance of active OCs in synovial tis-
sue, and erosive bone damage (12,13).
Given the emerging evidence that the SE acts as
a signal transduction ligand that directly contributes to
bone damage in arthritis, we explored ways to specifi-
cally inhibit this pathway. Here we describe a peptido-
mimetic SE-antagonistic ligand (SEAL) with highly
potent antiosteoclastogenic and antiarthritic effects.
These findings suggest that targeting the SE-activated
pathway might be a useful therapeutic strategy.
MATERIALS AND METHODS
Reagents, peptidomimetics, cells, and mice. Ficoll-
Paque, 4,5-diaminofluorescein diacetate (DAF-2-DA), macro-
phage colony-stimulating factor (M-CSF), RANKL, chicken
type II collagen, and Freund’s complete adjuvant (CFA) were
purchased from sources described previously (13). All other
commercial reagents were purchased from Sigma. Linear
5-mer peptides DKCLA, QKCLA, and DERAA, as well as
15-mer peptides 65–79*0401 (KDLLEQKRAAVDTYC) and
65–79*0404 (KDLLEQRRAAVDTYC), were synthesized and
purified (.90%) as described elsewhere (9,10). The urea
backbone cyclic peptidomimetics, designated generically as
HS(m-n)c Trp, were synthesized according to a previously
described procedure (21,22) using various alloc-protected gly-
cine building units, where m represents the number of methyl-
ene groups in the N-alkyl chain on the glycine building unit at
position 2, and n represents the number of methylene groups
in the N-alkyl chain on the glycine building unit at position 6.
A tryptophan residue at position 1 was used for tracing and
quantification.
The isolation of human peripheral blood mononuclear
cells (PBMCs) and mouse primary bone marrow cells (BMCs)
and the culture of M1 fibroblasts have previously been
described (13).
DBA/1 mice (6–10 weeks old) were purchased from
The Jackson Laboratory. Mice were maintained and housed
at the Unit for Laboratory Animal Medicine facility at the
University of Michigan. All experiments were performed in
accordance with protocols approved by the University Com-
mittee on Use and Care of Animals.
Surface plasmon resonance (SPR) analysis. A Biacore
2000 biosensor system was used to assay the interaction
between soluble ligands and recombinant mouse calreticulin
(6,11). SPR assay is based on a biosensor chip with a Dextran-
coated gold surface that is coated with a covalently immobi-
lized protein. Binding interactions between an injected ligand
(the “analyte”) and the immobilized protein result in SPR
signals that are directly proportional to the amount and
molecular mass of the ligand. Results are read in real time as
resonance units (RU).
Before use, biosensor chips CM5 (Biacore) were pre-
conditioned in water at 100 ml/minute by applying 2 consecu-
tive 20-ml pulses of 50 mM NaOH, followed by 10 mM HCl,
and finally 0.1% sodium dodecyl sulfate. The CM5 surface
was activated by a 7-minute injection of 200 mM 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloride in 50 mM
N-hydroxysuccinimide. Purified calreticulin was immobilized
by standard primary amine coupling at 258C in HBS-EP buffer
(10 mM HEPES, pH 7.4, 150 mM NaCl, 1 mM EDTA, and
0.005% surfactant P20), at a flow rate of 10 ml/minute. The
protein was injected manually at a concentration of 100 mg/ml
until approaching 5,500 RU. The remaining activated groups
were blocked by ethanolamine (1M).
Binding assays were performed at 258C in a binding
buffer (10 mM HEPES, pH 7.4, 50 mM KCl, 0.5 mM CaCl2,
100 mM ZnCl2, and 0.005% surfactant P20) at a flow rate of 10
ml/minute. Ligands were applied to the analyte at various con-
centrations. The RU signal intensity at a given molar concen-
tration is proportional to the molecular mass of the analyte.
Accordingly, when a competitive small ligand is mixed with a
larger ligand, a drop in the signal relative to the RU produced
by the latter ligand alone is observed. This characteristic was
used in our study to determine the competitive inhibition of
the binding of the 15-mer peptides 65–79*0401 (MW 1,751
daltons) or 15-mer peptide 65–79*0404 (MW 1,751 daltons) to
calreticulin by the 5-mer linear peptide DKCLA (MW 590 dal-
tons) or the cyclic DKCLA (cDKCLA) mimetic (MW 902 dal-
tons). All SPR data were calculated using the BIAevaluation
version 3.0.1 program (Biacore).
In vitro assays. Nitric oxide signal transduction assays
were performed using the nitric oxide probe DAF-2-DA. The
fluorescence level was recorded every 5 minutes over a period
of 500 minutes using a Fusion aHT system (PerkinElmer Life
Sciences) at an excitation wavelength of 488 nm and emission
wavelength of 515 nm. In vitro assays for OC differentiation
were performed using primary mouse BMCs isolated from
femurs and tibias or using human PBMCs isolated from
healthy blood donors. Mouse BMCs were cultured in 48-well
plates (2 3 105/well) a-minimum in essential medium supple-
mented with 10% fetal bovine serum, 100 units/ml of penicillin,
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Figure 1. Shared epitope–antagonistic ligand (SEAL) activity in vitro. A, Interaction between linear DKCLA peptide and recombinant calreticu-
lin. B, Specific inhibition of the interaction between SE ligand 65-79*0401 (171 mM) and calreticulin by linear DKCLA (508 mM). C, Specific
inhibition of the interaction between SE ligand 65–79*0404 and calreticulin by linear DKCLA. D, Dose-response inhibition of the interaction
between SE ligand 65–79*0401 (171 mM) and calreticulin by linear DKCLA. E, Dose-response inhibition of the interaction between SE ligand
65–79*0404 (169 mM) and calreticulin by linear DKCLA. F, Specific inhibition of SE ligand 65–79*0401 (57 mM)–activated nitric oxide (NO) sig-
naling by linear DKCLA (170 mM). ***5P , 0.001 for the indicated comparisons. G, Structural formula of the cyclic DKCLA compound
library. H, Dose-response curve showing the inhibitory effect of HS(4-4)c Trp on SE ligand 65–79*0401 (57 mM)–activated NO signaling. I, Com-
petitive inhibition of SE ligand 65–79*0401 (229 mM) binding to calreticulin by HS(4-4)c Trp. J, Inhibition of unstimulated (left) and SE ligand
65–79*0401 (29 mM)–activated (right) osteoclastogenesis in primary mouse bone marrow cells (BMCs) by HS(4-4)c Trp, as indicated by tartrate-
resistant acid phosphatase (TRAP)–positive cells. *5P , 0.05; **5P , 0.01 versus no treatment. K, No inhibition of osteoclastogenesis
in mouse BMCs by HS(3-4)c Trp. L, Inhibition of SE ligand–activated osteoclastogenesis in human peripheral blood mononuclear cells by
HS(4-4)c Trp and HS(3-3)c Trp. *5P , 0.05 versus 65–79*0401; #5P , 0.05 versus phosphate buffered saline (PBS). Values in F, J, K, and
L are the mean6 SEM. RU5 resonance units; FU5 fluorescence units; NS5not significant; IC505 50% inhibition concentration.
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and 100 mg/ml of streptomycin in the presence of 10 ng/ml of
M-CSF alone during the first 2 days, followed by 4 additional
days in the presence of 10 ng/ml of M-CSF plus 20 ng/ml of
RANKL.
Human OCs were differentiated from PBMCs derived
from random blood donors, irrespective of their HLA–DRB1
genotype. Cells (23 105/well) were cultured in 48-well plates for
7 days in 100 ng/ml of M-CSF and 100 ng/ml of RANKL supple-
mented with 10% fetal calf serum–Dulbecco’s modified Eagle’s
medium. To quantify the number of OCs, cultures were fixed
and stained for tartrate-resistant acid phosphatase (TRAP)
activity using an acid phosphatase kit (Kamiya Biomedical)
according to the manufacturer’s instructions. TRAP-positive
multinucleated OCs (.3 nuclei) were counted using a tissue-
culture inverted microscope.
CIA induction, in vivo compound administration, joint
tissue studies, and imaging. DBA/1 mice were immunized
with chicken type II collagen in CFA. Briefly, 50 ml of an
emulsion containing 100 mg of chicken type II collagen in 25
ml of 0.05M acetic acid and 25 ml of CFA was injected intra-
dermally at the base of the tail. Mice were injected intraperito-
neally once a week for 7 weeks with 50 ml of either phosphate
buffered saline (PBS), HS(4-4)c Trp, or HS(3-4)c Trp in PBS.
Arthritis severity was determined using a 4-point visual scoring
system for each paw, where 05 no arthritis, 15 swelling and
redness confined to the digits, 25minor swelling and redness
spreading from the digits to the distal paw, and 35major
swelling and redness extending proximally from the paw.
Limbs were dissected and decalcified in 10% EDTA.
After decalcification, the specimens were processed for paraf-
fin embedding and serial sectioning. The histology sections
were deparaffinized, rehydrated, and stained for TRAP activ-
ity using a commercial kit. To determine OC abundance,
TRAP-positive multinucleated cells were counted. Data are
reported as the mean6 SEM of the total number of OCs in
the front and hind paws plus both knees.
For micro–computed tomography (micro-CT), the
front and hind limbs were dissected, fixed in 10% formalin,
and stored in 70% ethanol. Limbs were scanned ex vivo with a
micro-CT system (eXplore Locus SP; GE Healthcare Canada)
in distilled water. The protocol included a source powered at
80 kV and 80 mA. In addition to a 0.508-mm aluminum filter,
an acrylic beam flattener was used to reduce beam-hardening
artifact. Exposure time was defined as 1,600 msec/frame, with
400 views taken at increments of 0.58. With 4 frames averaged
and binning at 2 3 2, the images were reconstructed with an
18-mm isotropic voxel size.
Radiographs were obtained using a microradiography
system (Faxitron) with the following operating settings: peak
voltage of 27V, anode current of 2.5 mA, and an exposure time
of 4.5 seconds. Coded radiographs were evaluated by an experi-
enced rheumatologist (JH) who was blinded with regard to the
treatment group. Bone erosions were scored on a scale of 0–5
for each of the 4 paws.
Docking models. BioMed CAChe 6.1 software (Fujitsu)
was used for modeling of the interaction between ligands and
the calreticulin P-domain. Cyclic peptidomimetics, which were
loaded as flexible molecules, or the physiologically folded SE
(residues 70–74 in the b-chain third allelic hypervariable region
of HLA–DR4; PDB ID 2SEB) as a rigid conformation, were
used as ligands. Rat calreticulin P-domain (PDB ID 1HHN) in
its rigid conformation was used as receptor. Docking scores were
calculated using BioMed CAChe 6.1 software. In all cases, the
minimum potential energy and chemical bonds were determined
for the most stable geometry.
Statistical analysis. Data are expressed as the mean6
SEM. Except where indicated otherwise, statistical analyses
were performed using Student’s t-test. P values less than 0.05
were considered significant.
RESULTS
DKCLA, a short linear synthetic peptide with
SEAL properties. We identified a 5-mer peptide express-
ing the sequence DKCLA that interacted with calreticulin
in an SPR-based assay (Figure 1A), and specifically inhib-
ited the interaction between calreticulin and 15-mer pep-
tide SE ligands corresponding to the 65–79 region coded
by HLA–DRB1*04:01 (Figure 1B) or by DRB1*04:04
(Figure 1C) at a 50% inhibition concentration (IC50) of 67
mM (Figure 1D) and 289 mM (Figure 1E), respectively.
Additionally, linear DKCLA specifically blocked SE
ligand–activated nitric oxide signaling (Figure 1F). Thus,
the linear peptide DKCLA is a low-potency competitive
inhibitor of the SE ligand, a functional characteristic
referred to as SE-antagonistic ligand.
DKCLA peptidomimetics. Linear peptides are
short-lived, and their biologic activity is further compro-
mised by their random conformation in solution.
Accordingly, as a peptide-stabilization strategy, we used
a previously described procedure (21,22) to synthesize a
library of backbone cDKCLA analogs, all carrying an
identical primary sequence, but differing in the size of
their ring (Figure 1G). Members of this library were
screened in SE ligand–activated nitric oxide signaling
assays to determine the relative SEAL potency of indi-
vidual compounds in vitro. Of the 16 analogs tested, sev-
eral were found to be exceptionally potent (e.g., the
compounds HS[4-4]c Trp, HS[3-3]c Trp, and HS[6-4]c
Trp) (Table 1), with IC50 values as low as 1.6 3 10
212M
(Figure 1H). The lead compound HS(4-4)c Trp was
tested in SPR assays, and was found to be a potent
Table 1. Differential inhibition of shared epitope–activated nitric
oxide signaling by cDKCLA compounds*
cDKCLA compound IC50, M
HS(4-4)c Trp 1.6 3 10212
HS(3-3)c Trp 1.8 3 10212
HS(6-4)c Trp 6.3 3 1029
HS(4-6)c Trp 5.6 3 1027
HS(6-2)c Trp 7.7 3 1027
HS(3-4)c Trp 4.3 3 1026
* The cyclic DKCLA (cDKCLA) compounds examined are urea back-
bone cyclc peptidomimetics. IC505 50% inhibition concentration.
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competitive inhibitor of SE–calreticulin interaction,
with an IC50 of 2.4 3 10
212M (Figure 1I). Thus,
cDKCLA compound HS(4-4)c Trp is a 1,000,000 times
more potent SEAL than the linear DKCLA peptide.
In vitro inhibition of OC differentiation by
cDKCLA compounds. Since OCs play a key role in bone
erosion–associated conditions, an attempt to inhibit these
cells is a desirable therapeutic goal. Given the high SEAL
potency of compounds HS(4-4)c Trp and HS(3-3)c Trp in
signal transduction (Table 1), we carried out experiments
to determine their effectiveness as OC inhibitors.
We found that in mouse cells (Figure 1J), the
lead cDKCLA compound HS(4-4)c Trp very efficiently
inhibited RANKL-activated OC differentiation. Moreover,
Figure 2. Amelioration of collagen-induced arthritis (CIA) by HS(4-4)c Trp. A, HS(4-4)c Trp at either 36 pg (blue) or 360 pg (red) per gram of
body weight or phosphate buffered saline (PBS) (black) was administered intraperitoneally once a week for 7 weeks (n5 10 mice per group),
and the day of arthritis onset was recorded. Each symbol represents a single mouse; horizontal lines with bars show the mean6SEM. B, Inci-
dence of arthritis over 45 days in the 3 treatment groups. C, Arthritis scores over 45 days in the 3 treatment groups. Values are the mean-
6 SEM. P values are versus PBS, by paired t-test. D, Synovial osteoclasts in the joints of mice in the 3 treatment groups, as indicated by tartrate-
resistant acid phosphatase (TRAP)–positive cells. Values are the mean6 SEM of 5 mice per group. E, Histologic features of the wrist in mice
with CIA treated with PBS or with 360 pg/gm of HS(4-4)c Trp. Sections were stained with TRAP (original magnification 3 4) or with hematoxy-
lin and eosin (H&E) (original magnification 3 100). The region indicated by the white arrow at the top left corner of the TRAP-stained section
from the mouse treated with PBS is shown at higher magnification in the inset. F, Micro–computed tomography images of the front (left) and
hind (right) paws of mice with CIA treated with PBS (top), 36 pg/gm of HS(4-4)c Trp (middle), or 360 pg/gm of HS(4-4)c Trp (bottom). G,
Bone erosion scores in the 3 treatment groups. Each symbol represents a single mouse; horizontal lines with bars show the mean6 SEM. In A
and G, **5P , 0.01; ***5P , 0.001 versus PBS.
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it significantly inhibited the incremental SE-activated OC
differentiation. SEAL activity was found to be structure-
specific, since the cDKCLA analog HS(3-4)c Trp, which
carries an identical core amino acid sequence and only dif-
fers in the ring size, failed to inhibit OC differentiation
(Figure 1K), consistent with its low inhibitory effect in sig-
nal transduction studies (Table 1). The antiosteoclasto-
genic effects of SEAL compounds HS(4-4)c and HS(3-3)c
were tested in human PBMCs as well, and showed potent
antiosteoclastogenic effects in the absence or presence of
an exogenously added SE ligand (Figures 1J and L). The
effect was found in both SE-positive and SE-negative
PBMCs (results not shown). Additionally, preliminary
data suggest that similar to their effect on PBMC-derived
OCs, SEAL compounds inhibited signal transduction in
human fibroblast-like synoviocytes irrespective of the SE
status of the donor as well (results not shown).
Cyclic DKCLA analog–specific effects in vivo. The
effects of SEAL compounds were studied in mice with
CIA. As shown in Figure 2, mice injected intraperitone-
ally once a week with picogram doses of HS(4-4)c Trp
experienced delayed onset (Figure 2A), lower incidence
(Figure 2B), and significantly milder (Figure 2C) arthri-
tis. Histologically, their joints showed less-abundant
OCs in the synovial tissues (Figures 2D and E). Interest-
ingly, although at the end of the treatment period (day
45 postimmunization) joint swelling was seen in all
groups, pannus from PBS-treated mice showed greater
lymphocytic infiltration than did the synovial tissue from
HS(4-4)c Trp–treated mice (Figure 2E). Micro-CT and
radiographic imaging demonstrated a lesser extent of
bone destruction in the treated groups (Figures 2F and
G). In contrast and consistent with its inactivity in vitro,
the HS(3-4)c Trp analog had no effect on the day of
arthritis onset (Figure 3A), the incidence of arthritis
(Figure 3B), the disease severity (Figure 3C), the radio-
graphic bone damage (Figure 3D), or the abundance of
OCs in synovial tissues (Figure 3E).
No behavioral, physical, radiologic, or histologic
aberrations were noticed in SEAL-treated mice as com-
pared to controls. Untreated and treated mice (highest
dosage 360 pg/gm of body weight weekly for up to 7
weeks) showed similar general health parameters (body
weight, fur appearance, mobility, and food and water
consumption rates).
As mentioned above, the compounds HS(4-4)c
Trp and HS(3-4)c Trp share an identical core sequence,
but differ slightly in their ring size. This minor structural
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dissimilarity nevertheless accounted for a major func-
tional disparity between the 2 compounds. To gain bet-
ter insights into the structure–function correlates of the
2 compounds, we docked them virtually onto a physio-
logically folded calreticulin P-domain (6), using BioMed
CAChe 6.1 software.
Compounds HS(4-4)c Trp and HS(3-4)c Trp were
both predicted to occupy the SE binding pocket (Figure
4); however, their respective chemical interactions within
the binding pocket and their docking energies were dis-
tinct (Table 2). The lead SEAL compound HS(4-4)c Trp
had a higher docking energy than the inactive analog
HS(3-4)c Trp and engaged in a dual chemical bond with
a single calreticulin residue (Glu257). The inactive com-
pound HS(3-4)c Trp, on the other hand, interacted
weakly with 3 calreticulin residues: Asp209, Glu223, and
Gly256. For comparison, a similarly docked SE ligand in
its native a-helical conformation had a single electrostatic
bond with calreticulin residue Glu223 and a dual electro-
static bond with residue Asp209. Thus, the inactive analog
HS(3-4)c Trp, similar to the naturally folded SE ligand,
was predicted to generate a “bridging” effect across the SE
binding pocket, while the SEAL compound HS(4-4)c Trp
displayed a strong focal interaction with calreticulin residue
Glu257 at the center of that pocket (Figure 4). Taken
together, the data in Figure 4 and Table 2 indicate that
despite their nearly identical chemical structure, the 2 func-
tionally disparate compounds displayed distinct molecular
interactions with the SE binding site on calreticulin.
DISCUSSION
The main significance of the findings reported
herein is the identification of the SE/calreticulin pathway
as a novel therapeutic target. To date, treatment modal-
ities in RA have targeted cytokines, their receptors, or
Table 2. Ligand–calreticulin docking characteristics*
Interacting residues†
Ligand
(core aa sequence)
Docking energy,
kcal/mole Calreticulin Ligand Distance, A˚
Chemical
bond
SE (70QKRAA74) 2207 Asp209 R72 3.5 ESB
Asp209 R72 3.5 ESB
Glu223 K71 3.2 ESB
HS(4-4)c Trp (DKCLA) 2109 Glu257 K 2.1 HB
Glu257 K 2.6 ESB
HS(3-4)c Trp (DKCLA) 221.9 Asp209 A 1.8 HB
Glu223 D 2.1 HB
Gly256 D 2.1 HB
* Two urea backbone cyclic peptidomimetics were examined: HS(4-4)c Trp and HS(3-4)C Trp. SE5 shared
epitope; ESB5 electrostatic bond; HB5 hydrogen bond.
† Calreticulin residues are shown in the 3-letter format, and the numbers correspond to the location of the
given amino acid (aa) residue in the calreticulin sequence. Ligand residues are shown in the single-letter for-
mat, and the numbers correspond to the location of the amino acid residue in the DRb chain sequence.
Figure 4. Docking models for A, the shared epitope (SE), B, the mimetic compound HS(4-4)c Trp, and C, the mimetic compound HS(3-4)c
Trp. Ligands (blue) are docked to the calreticulin (CRT) surface (tan). Side chains of interacting calreticulin residues are highlighted in orange.
Dotted lines represent chemical bonds. Red areas represent the surface of key calreticulin residues that interact with the ligands. Insets depict
the chemical interactions. The calreticulin residues are identified in 3-letter format and the ligand residues in single-letter format.
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other players in the immune-activated final common
pathway. Due to their involvement in “downstream” seg-
ments of RA pathogenesis, these targets are often redun-
dant and/or nonspecific. As a result, current treatment
modalities are often ineffective, and/or they carry high
rates of side effects, mainly infection (23). The advantage
of a SEAL-based therapeutic approach over current or
emerging drugs is that it addresses an unmet need by
offering a potent intervention strategy that specifically tar-
gets an “upstream” segment of the pathogenic cascade.
The compounds described herein were found to
be highly potent, both in vitro and in vivo. For example,
compounds HS(4-4)c Trp and HS(3-3)c Trp competi-
tively blocked SE signaling effects and inhibited OC dif-
ferentiation at low picomolar concentrations, a 1,000-
fold higher potency than JAK inhibitors (24). The in
vivo effect of compound HS(4-4)c Trp, likewise, was
much more potent than that of emerging drugs reported
to exert therapeutic efficacy in CIA at doses in the
milligram-per-kilogram range (24–26). In contrast, com-
pound HS(4-4)c Trp described herein achieved disease-
amelioration effects at doses in the nanogram-per-
kilogram range, a 1,000,000-fold higher potency.
Interestingly, despite its seemingly modest anti-
osteoclastogenic effect in vitro (Figures 1J and L),
SEAL compound HS(4-4)c Trp was highly effective in
diminishing tissue OCs when administered in vivo to
mice with CIA (Figure 2D). The likely explanation for
the apparent discrepancy is that in vitro assays do not
accurately replicate the cellular events that take place in
vivo. Specifically in this case, in vitro OC-differentiation
assays were carried out using mouse BMCs (Figure 1J)
or human PBMCs (Figure 1L), while in vivo, the abun-
dance of OCs was determined within mouse synovial
tissue, which represents a different cellular milieu. Sec-
ond, in vitro OC-differentiation protocols used selected
pro-osteoclastogenic factors (M-CSF and RANKL),
whereas the in vivo process involved additional pro-
osteoclastogenic and antiosteoclastogenic factors. Third,
the in situ concentrations of RANKL and M-CSF are
likely to be lower than those used to artificially stimulate
robust OC differentiation in vitro.
SEAL compound–treated CIA mice showed
delayed arthritis onset and decreased incidence; how-
ever, both the treated and control groups eventually
developed joint swelling and reached equivalent disease
incidence. This observation is consistent with our previ-
ous studies demonstrating that the arthritogenic effect
of SE agonist ligands affect joint swelling in the early
phase of CIA, but less so in the chronic phase (12,13).
The mechanistic basis of the differential effect on early
versus late joint swelling is unknown, but is likely to be
related to the fact that the early and late stages of CIA
are distinct in their pathogenic mechanisms and in the
degree of their responsiveness to therapeutic interven-
tions (27–31). Similarly consistent with our previous
findings with SE agonist ligands (12,13), which demon-
strated a disproportionate impact on bone erosions rela-
tive to their effects on joint swelling, the SEAL
compound reversed this trend by affecting primarily
bone damage. Such a differential effect is not without
precedent, as disparate severities of joint inflammation
versus bone erosion have previously been reported in
experimental arthritis models (32,33) as well as in RA in
humans (34). Better understanding of the mechanisms
governing bone selectivity by SEAL compounds could
provide important new insights into the pathogenic
mechanisms that specifically underlie inflammation ver-
sus bone damage.
It should be pointed out that SEAL compounds
inhibited basal osteoclastogenesis in vitro even in the
absence of the SE ligand and ameliorated CIA in mice
that do not carry SE-coding MHC class II alleles.
Therefore, consistent with the SE ligand theory (for a
discussion, see refs. 35 and 36), it is reasonable to pro-
pose the existence of a physiologic calreticulin-binding
ligand capable of OC activation during healthy bone
remodeling. There are several physiologic ligands that
the SE ligand could potentially mimic. For example, cir-
culating levels of adiponectin, a known calreticulin
ligand (37), have been shown to correlate with the
extent of radiographic bone damage in RA (38). It is
noteworthy that adiponectin facilitates Th17 polariza-
tion (39) and can activate OCs (for review, see ref. 40).
Thrombospondin 1, likewise a well-characterized calre-
ticulin ligand (41) that is implicated in RA pathogenesis
(42,43), facilitates Th17 polarization (44) and activates
OCs (45).
Obviously, identification of the specific physiologic
calreticulin ligand that the SE may be mimicking requires
further study. However, irrespective of the identity of that
physiologic ligand, the model proposed here hypothesizes
that the SE may facilitate OC activation and bone dam-
age by mimicking a putative physiologic ligand. Accord-
ingly, SEAL compounds may ameliorate OC activation
and arthritis through competitive inhibition of a physio-
logic ligand, independently of the presence or absence of
an SE ligand. This model further posits that individuals
with SE-coding HLA–DRB1 alleles are at higher risk of
developing erosive arthritis due to the high abundance of
cell surface SE-expressing HLA–DR molecules that
mimic the physiologic OC-activating ligand. Under cer-
tain genetic and environmental circumstances, the SE
ligand may overactivate the innate pathway, with resultant
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excessive activation of OCs. In this context, it is worth
noting that SE-associated bone damage is not unique to
RA, as SE-coding HLA–DRB1 alleles have been shown
to associate with accelerated bone erosion in patients
with psoriatic arthritis (46), patients with periodontal dis-
ease (47), and patients with SLE (48).
Beyond offering new insights into the pathogene-
sis of bone damage in arthritis, our findings illustrate
the therapeutic targetability of the SE/calreticulin path-
way by highly specific, rationally designed SEAL com-
pounds. The compounds presented here were highly
potent, both in vitro and in vivo, and showed exquisite
structure–activity relationships. These facts could facili-
tate future compound optimization efforts. From a
medicinal chemistry perspective, it is also worth noting
that the cysteine residue does not appear to play a role
in the antagonist’s interaction model with calreticulin
(Figure 4 and Table 2). Additionally, since the inactive
compound HS(3-4)c Trp contains cysteine in the same
position as the active compounds HS(4-4)c Trp and
HS(3-3)c Trp, the cysteine residue, including its thiol
side chain, is unlikely to play a functional role in the bio-
logic effects of these compounds.
The new strategy presented herein may be safer
than using prevailing drugs because of the unique role
played by this pathway at an “upstream” phase in RA
pathogenesis. The SE is the single most significant risk
factor for RA. It determines susceptibility, severity, and
disease penetrance (49). Thus, different from effector
cytokines or intracellular enzymes, this pathway is
involved in the early segments of disease etiology and
pathogenesis. Targeting such an “upstream” pathway
might be more effective and would likely produce fewer
side effects.
In conclusion, the findings of this study suggest
that SEAL compounds could be useful tools for examin-
ing the mechanisms governing bone erosion in various
conditions, including RA. Furthermore, the results pro-
vide a rationale and early medicinal information that
could help in the development of specific, potent, safe,
and inexpensive drugs for arthritis and other erosive
bone conditions.
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